Epilepsy Therapeutic Market in APAC 2017-2021

  • ID: 4307499
  • Report
  • Region: Asia Pacific
  • 81 pages
  • TechNavio
OFF
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 5

FEATURED COMPANIES

  • Eisai
  • GlaxoSmithKline
  • Pfizer
  • UCB
  • MORE
About Epilepsy Therapeutic

Epilepsy is a neurological condition that affects the nervous system. It is characterized by the occurrence of two or more unprovoked seizures. A seizure is defined as the disruption of electrical communication between neurons. The central nervous system (CNS) disorders include several disorders and conditions such as epilepsy, Parkinson's disease, bipolar disorder, and depression.

The analysts forecast the epilepsy therapeutic market in APAC to grow at a CAGR of 4.25% during the period 2017-2021.

Covered in this report
The report covers the present scenario and the growth prospects of the epilepsy therapeutic market in APAC for 2017-2021. To calculate the market size, the report considers the sales of branded, generic, and off label drugs.

The market is divided into the following segments based on geography:
- Americas
- APAC
- EMEA

The report, Epilepsy Therapeutic Market in APAC 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the Key vendors operating in this market.

Key vendors
- Eisai
- GlaxoSmithKline
- Pfizer
- UCB

Other prominent vendors
- Dainippon Sumitomo Pharma
- Janssen Pharmaceutical (a division of Johnson & Johnson)

Market drivers
- High unmet medical need
- For a full, detailed list, view the full report

Market challenges
- Technological advancements in non-invasive neuromodulation and seizure management devices - A threat to drug therapies
- For a full, detailed list, view the full report

Market trends
- Reformulation of marketed drugs
- For a full, detailed list, view the full report

Key questions answered in this report
- What will the market size be in 2021 and what will the growth rate be?
- What are the key Market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are theKey vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?

You can request one free hour of the analyst’s time when you purchase this market report. Details are provided within the report.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Eisai
  • GlaxoSmithKline
  • Pfizer
  • UCB
  • MORE
PART 01: Executive summary

PART 02: Scope of the report

PART 03: Research Methodology

PART 04: Introduction
  • Market outline
PART 05: Disease overview
  • Signs and symptoms
  • Generalized seizure
  • Focal seizure
  • Non-convulsive seizure
PART 06: Market landscape
  • Market overview
  • Market size and forecast
  • Five forces analysis
PART 07: Pipeline analysis

PART 08: Market segmentation based on product type
  • First-generation epilepsy therapeutics
  • Second-generation epilepsy therapeutics
  • Third-generation epilepsy therapeutics
PART 09: Geographical segmentation
  • Epilepsy therapeutics market scenario in Japan
  • Market scenario in Australia
  • Market scenario in China
  • Market scenario in India
PART 10: Decision framework

PART 11: Drivers and challenges
  • Market drivers
  • Market challenges
PART 12: Market trends
  • Reformulation of marketed drugs
  • Emergence of new-generation AEDs
  • AEDs with novel mechanism of action
PART 13: Vendor landscape
  • Competitive landscape
PART 14: Key vendor analysis
  • Eisai
  • GlaxoSmithKline
  • Pfizer
  • UCB
  • Other prominent vendors
PART 15: Appendix
  • List of abbreviations
List of Exhibits
Exhibit 01: Global CNS therapeutics market segmentation based on disease type
Exhibit 02: Epilepsy therapeutics market scenario based on countries
Exhibit 03: Types of epilepsy disorder
Exhibit 04: Signs and symptoms of epilepsy
Exhibit 05: Types of generalized seizure
Exhibit 06: Types of focal seizure
Exhibit 07: Epilepsy therapeutics market in APAC snapshot
Exhibit 08: Epilepsy therapeutics market in APAC 2016-2021 (in $ million)
Exhibit 09: Opportunity analysis in epilepsy therapeutics market in APAC
Exhibit 10: Five forces analysis
Exhibit 11: Pipeline landscape
Exhibit 12: Key clinical trials: Therapeutics
Exhibit 13: Key clinical trials: Enhanced drug delivery
Exhibit 14: Key clinical trials: Dietary supplement
Exhibit 15: Segmentation of epilepsy therapeutics market in APAC on product type
Exhibit 16: Market share of epilepsy therapeutics market in APAC based on product type 2016
Exhibit 17: Approval scenario: First-generation epilepsy therapeutics
Exhibit 18: First-generation epilepsy therapeutics market in APAC 2016-2021 ($ millions)
Exhibit 19: Second-generation epilepsy therapeutics market in APAC 2016-2021 ($ millions)
Exhibit 20: Third-generation epilepsy therapeutics market in APAC 2016-2021 ($ millions)
Exhibit 21: Segmentation of epilepsy therapeutics market in APAC by geography 2016 and 2021 (%)
Exhibit 22: Epilepsy therapeutics market revenue in APAC by geography 2016-2021 ($ millions)
Exhibit 23: Epilepsy therapeutics market share in APAC by geography 2016-2021 (%)
Exhibit 24: Market scenario in Japan
Exhibit 25: Epilepsy therapeutics market in Japan 2016-2021 ($ millions)
Exhibit 26: Market scenario in Australia
Exhibit 27: Epilepsy therapeutics market in Australia 2016-2021 ($ millions)
Exhibit 28: Market scenario in China
Exhibit 29: Epilepsy therapeutics market in China 2016-2021 ($ millions)
Exhibit 30: Market scenario in India
Exhibit 31: Epilepsy therapeutics market in India 2016-2021 ($ millions)
Exhibit 32: Epilepsy scenario in developed countries versus developing countries
Exhibit 33: Impact of loss of exclusivity for LYRICA in Canadian and European market ($ millions)
Exhibit 34: Competitive structure analysis of epilepsy therapeutics market in APAC 2016
Exhibit 35: Eisai: Key highlights
Exhibit 36: Eisai: Strength assessment
Exhibit 37: Eisai: Strategy assessment
Exhibit 38: Eisai: Opportunity assessment
Exhibit 39: GlaxoSmithKline: Strength assessment
Exhibit 40: GlaxoSmithKline: Strategy assessment
Exhibit 41: GlaxoSmithKline: Opportunity assessment
Exhibit 42: Pfizer: Key highlights
Exhibit 43: Pfizer: Strength assessment
Exhibit 44: Pfizer: Strategy assessment
Exhibit 45: Pfizer: Opportunity assessment
Exhibit 46: UCB: Key highlights
Exhibit 47: UCB: Strength assessment
Exhibit 48: UCB: Strategy assessment
Exhibit 49: UCB: Opportunity assessment
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • Eisai
  • GlaxoSmithKline
  • Pfizer
  • UCB
  • MORE
New Report Released: – Epilepsy Therapeutic Market in APAC 2017-2021

The author of the report recognizes the following companies as the key players in the epilepsy therapeutic market in APAC: Eisai, GlaxoSmithKline, Pfizer, and UCB.

Other Prominent Vendors in the market are: Dainippon Sumitomo Pharma and Janssen Pharmaceutical (a division of Johnson & Johnson).

Commenting on the report, an analyst from the research team said: “The latest trend gaining momentum in the market is reformulation of marketed drugs. Drug delivery systems such as transdermal patches, extended-release (ER) formulations, and orally disintegrating tablets increase the efficacy of drugs either by increasing the patient compliance or by increasing the bioavailability of the drug. The reformulation of marketed drugs also provides an opportunity to grab patent term extensions, which can delay the entry of generic versions in the market.”

According to the report, one of the major drivers for this market is high unmet medical need. The epilepsy therapeutics market in APAC is currently witnessing a high unmet medical need in terms of the lack of any disease-modifying treatment. At present, drugs administered during epilepsy are intended to treat seizures, i.e., these are symptomatic in nature, which helps in suppressing symptoms (seizures) and provides substantial assistance to individuals.

Further, the report states that one of the major factors hindering the growth of this market is technological advancements in non-invasive neuromodulation and seizure management devices - A threat to drug therapies. A majority of the population treated with traditional AEDs still continue to suffer from their side effects such as weight gain, muscle spasm, blurred vision, dry mouth, and drowsiness. Hence, alternative methods were being investigated, and devices were developed for the individuals who do not respond to medications.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 5
  • Eisai
  • GlaxoSmithKline
  • Pfizer
  • UCB
  • Dainippon Sumitomo Pharma and Janssen Pharmaceutical (a division of Johnson & Johnson).
Note: Product cover images may vary from those shown
6 of 5
Note: Product cover images may vary from those shown
Adroll
adroll